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Abstract For the improved production of vaccines and
therapeutic proteins, a detailed understanding of the met-
abolic dynamics during batch or fed-batch production is
requested. To study the new human cell line AGE1.HN, a
ﬂexible metabolic ﬂux analysis method was developed that
is considering dynamic changes in growth and metabo-
lism during cultivation. This method comprises analysis of
formation of cellular components as well as conversion of
major substrates and products, spline ﬁtting of dynamic
data and ﬂux estimation using metabolite balancing. Dur-
ing batch cultivation of AGE1.HN three distinct phases
were observed, an initial one with consumption of pyruvate
and high glycolytic activity, a second characterized by a
highly efﬁcient metabolism with very little energy spilling
waste production and a third with glutamine limitation and
decreasing viability. Main events triggering changes in
cellular metabolism were depletion of pyruvate and glu-
tamine. Potential targets for the improvement identiﬁed
from the analysis are (i) reduction of overﬂow metabolism
in the beginning of cultivation, e.g. accomplished by
reduction of pyruvate content in the medium and (ii)
prolongation of phase 2 with its highly efﬁcient energy
metabolism applying e.g. speciﬁc feeding strategies. The
method presented allows fast and reliable metabolic ﬂux
analysis during the development of producer cells and
production processes from microtiter plate to large scale
reactors with moderate analytical and computational effort.
It seems well suited to guide media optimization and
genetic engineering of producing cell lines.
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Introduction
Cell culture products represent currently the most impor-
tant and most promising source for new biopharmaceuti-
cals. The majority of recombinant biopharmaceuticals
are produced by mammalian cell culture and this fraction
is steadily increasing [1–3]. The projected sales volume
for therapeutic proteins by 2010 is USD 70 billion [4, 5].
Commonly employed production cell lines are, e.g.,
ChineseHamsterOvary(CHO)cellsormurinelymphoidcells.
These production systems must be capable of generating
high quantities of proteins to enable the administration of
high doses required in clinical application [6–8]. A number
of approaches were applied to optimize product yields [9],
e.g., cell cycle arrest and control of apoptosis [10–13]o r
addition of nutrient supplements [14–16]. However, there
is still room for improvement. New production cell lines
are entering the market due to demands for higher product
quality (e.g., glycosylation), efﬁciency, productivity and
robustness. Cell lines created from primary cells represent
promising new production systems. These cell lines over-
come typical limitations of other cells as for example
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also the repeated safety testing required for each new batch
of primary tissue [17]. Concerning manufacturing of ther-
apeutic proteins, engineered human cell lines may have in
particular another unique advantage over standard producer
cell lines, as for example CHO cells, because of their
genuine human post-translational modiﬁcation machinery.
The cell line AGE1.HN represents such a new human cell
line which was immortalized and engineered for apoptosis
resistance and can be used for production of recombinant
proteins but also for viruses and viral vectors. However,
further targeted optimization would be promoted by a
profound knowledge of growth and metabolism of the
cells. In order to ﬁnd optimized cultivation conditions and
targets for metabolic engineering for improved production
metabolic ﬂux analysis seems most suited since it repre-
sents the functional end point of genome, proteome and
metabolome interactions [18, 19]. This methodology has
revealed valuable insights into the metabolism of several
mammalian cell systems [20–24]. A requirement for reli-
able stationary metabolic ﬂux analysis is metabolic steady
state that is usually not reached due to complex growth
requirements. It seems generally possible to optimize the
medium such that metabolic steady state is reached during
a longer period [25]. However, if the metabolism of cells in
a conventional medium should be investigated, dynamic
changes of the cellular metabolism commonly observed in
cell culture [26] have to be monitored and considered. One
way to deal with this challenge is to focus just on the
exponential growth phase of the cells where in some cases
metabolic steady state can be observed [22]. Another
possibility is to divide the growth of the cells in different
metabolic phases and calculate the ﬂux distribution for
each phase [26]. The third possibility is to compute
instantaneous ﬂux distributions during the whole cultiva-
tion [27]. Most detailed information can be obtained using
13C-substrate labeling techniques. This can be accom-
plished either assuming intracellular steady state of
metabolites [28] or analyzing intracellular metabolite and
isotopomer dynamics. The latter requires much more
sophisticated analytical methods and is much more labo-
rious both for analysis as well as modeling and computa-
tion [29, 30].
In this study we quantitatively analyze dynamics of
growth and metabolism of the new human cell line
AGE1.HN using a dynamic ﬂux analysis method. The
presented method of metabolic ﬂux analysis is well suited
to monitor and investigate metabolic shifts caused by
environmental changes that occur during batch cultivation
of mammalian cells. It does not require any kinetic model
and is therefore widely applicable. Estimated ﬂux dynam-
ics were compared to results obtained from stationary
metabolic ﬂux analysis in different metabolic phases. We
analyzed parental AGE1.HN cells in this study to gain
detailed quantitative knowledge and understanding of
growth behavior, cellular metabolism as well as its
dynamics. The results are therefore expected to be useful
for rational development of optimal growth media, for
further optimization and engineering of the cell line to
obtain higher cell densities in a process but also for all
derived producer cells and for the design of other producer
cell lines.
Materials and methods
Cell line
The AGE1.HN cell line was developed from primary cells
from a human brain tissue sample. The primary cells were
immortalized with an expression plasmid containing the
adenoviral E1 A and B genes of human adenovirus type 5
driven by the human pGK and the endogenous E1B pro-
moter, respectively. While the E1A induces progression of
the cell cycle, the E1B proteins prevent apoptosis caused
by E1A through interaction with P53 and bax. The cell line
was further modiﬁed to express the structural and regula-
tory protein pIX from human adenovirus type 5. This
modiﬁcation changes cell metabolism, enhances produc-
tivity for secreted proteins and modulates susceptibility to a
variety of viruses. The AGE1.HN cells express marker
genes representative for cells of neuronal lineage and lack
expression of glial markers. The cell line was adapted to
robust growth in suspension in both serum/protein-free and
chemically deﬁned culture media and has been proven to
grow efﬁciently in shaker, spinner, roller and stirred tank
bioreactors. The entire development work for the genera-
tion of the AGE1.HN line was carried out in a dedicated
cell culture suite and the complete development history
was recorded. The documentation for all media and sup-
plements used in the AGE1.HN cell line development is
in compliance with the stipulations of EMEA 410/01.
The AGE1.HN cell line is proprietary to ProBioGen AG
(Berlin,Germany)coveredbypatentapplication06807777.5-
2406.
Cell culture and experimental procedure
The cells were cultured in bafﬂed shake ﬂasks (Corning,
NY, USA) at 37 C on a shaker (2 inches orbit, ES-X,
Ku ¨hner, Basel, Switzerland) enclosed in a 5% CO2 sup-
plied, humidiﬁed (80%) incubator (Mytron, Heilbad Heil-
igenstadt, Germany). The pre-culture was carried out in a
250 ml bafﬂed shake ﬂask in 42-Max-UB-medium which
is serum-free and was especially developed for the
AGE1.HN cell line. The medium composition is presented
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123in Table S1. The cells were centrifuged (800 l min
-1,
7 min, 22 C, Megafuge, Heraeus Instruments, Hanau,
Germany) and the supernatant discarded. The pellet was
resuspended in 42-Max-UB-medium without glucose and
glutamine. Four 125-ml bafﬂed shake ﬂasks were inocu-
lated yielding an initial cell density of about 4 9 10
5 cells
ml
-1. Glucose and glutamine were ﬁnally added. The ﬁnal
culture volume was 54 ml. Samples (1.6 ml) were taken
every day. 500 ll were directly used for cell counting. The
rest was centrifuged (1,500 l min
-1, 5 min, 22 C, Mega-
fuge, Heraeus Instruments, Hanau, Germany), the super-
natant transferred into fresh tubes and frozen (-20 C).
The analysis of several cultivation parameters was carried
out using an automated cell culture analyzer (Cedex AS20,
Innovatis, Bielefeld, Germany) which determines cell
density, viability (Trypan Blue exclusion method), size,
morphology and aggregation rate. Dissolved oxygen was
always above 80% in the applied setup which was deter-
mined in an additional cultivation using the OXY-4 mini
system (PreSens-Precision Sensing GmbH, Regensburg,
Germany) described earlier [31].
Quantiﬁcation of metabolites
Glucose, lactate and pyruvate in the supernatant were
analyzed using high pressure liquid chromatography
(HPLC) as described previously [22]. Quantiﬁcation of
proteinogenic amino acids was performed by another
HPLC method [32]. The measured metabolite concentra-
tions as well as cell density were corrected for evaporation
using Eq. 1. The determined evaporation rate kE in the
applied setup was 0.0356 h
-1.
ccorr ¼ cmeas  
100
100 þ t   kE ðÞ
ð1Þ
ccorr represents the corrected concentration and cmeas the
measured concentration.
Glutamine hydrolysis was observed to be a ﬁrst order
process having a rate constant kG of 0.00198 h
-1 in the
applied medium (pH 7.4, 37 C). The actual glutamine
uptake rate rGln was calculated employing polynomials of
degree 5 in Matlab 7.5 (The Mathworks, Natick, MA,
USA) using
d Gln ½ 
dt
¼ kG   Gln ½  þ rGln ðÞ : ð2Þ
Metabolic network
A metabolic network model (Fig. 1) was set up using the
Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway database for Homo sapiens as well as other pub-
lished metabolic network information [33]. The enzymes
that were included into the model are given in Table S4 of
the supplementary material section. The stoichiometric
matrix of the model had the dimensions 41 9 70 and a
rank of 41. It is presented in the supplementary material
(Table S5).
Central energy metabolism
The main pathways of the energy metabolism, glycolysis,
oxidative decarboxylation, TCA cycle, electron transport
chain and oxidative phosphorylation are represented. Due to
the possible action of nicotinamide nucleotide transhydro-
genases and the fact that for some reactions it is not known
whether NADH or NADPH take part, NADH and NADPH
were lumped together. The excess of NAD(P)H and FADH2
from all reactions considered in the model was calculated.
For oxidative phosphorylation, it was assumed that per
NAD(P)H and FADH2 2.5 ATP and 1.5 ATP are produced,
respectively. The excess of ATP (ATPtot) was calculated
considering the demand or production of all reactions.
However, the energy needed for transport of metabolites
and maintenance was not included in the ATP-balance.
Pentose phosphate pathway
Pentose phosphate pathway/glycolysis split cannot be
resolved by metabolite balancing alone and was assumed to
be just responsible for nucleic acid synthesis.
Amino acid metabolism
The metabolism of proteinogenic amino acids is repre-
sented by selected degradation pathways. In cases where
several pathways are possible, the most probable and
suitable pathway was chosen (Table S4 of supplementary
material; Fig. 1).
Other reactions
Since it is not possible to distinguish between the reactions
catalyzed by the enzymes phosphoenolpyruvate carboxy-
kinase, malic enzyme (malate dehydrogenase, oxaloacetate
decarboxylating) and pyruvate carboxylase with the
method applied in this study, just one reaction from malate
to pyruvate was included which represents the sum of the
ﬂuxes through these enzymes.
Synthesis of biomass
The biomass ﬂuxes are represented as ﬁve ﬂuxes to the
major macromolecules of the cell. Cytosolic acetyl coen-
zyme A, which is needed for the synthesis of fatty acids
and lipids, is assumed to be solely derived from citrate that
is transported through the citrate/malate shuttle and
Bioprocess Biosyst Eng (2011) 34:533–545 535
123converted through the citrate lyase to acetyl coenzyme
A and malate. Further precursors that were considered for
the synthesis of lipids are glyceraldehyde 3-phosphate
and serine. Carbohydrates were taken as polyglucose and
are therefore derived from glucose 6-phosphate. The pre-
cursors considered for nucleic acid synthesis are ribose
5-phosphate, glycine and aspartate. For proteins, a certain
amount of each proteinogenic amino acid is needed per cell
which was calculated using the amino acid composition of
total cellular protein determined in this study (described
below).
Transport of metabolites
As mentioned above the energy demand for transport was
not included in the ATP balance. From calculated ﬂuxes, a
rough estimate could however be derived using literature
knowledge, e.g., about amino acid transport [34]. The
mitochondrial transporters included in the model are the
pyruvate carrier, citrate/malate shuttle, glutamate/aspartate
shuttle and the ADP/ATP transporter [35, 36]. For further
metabolites entering the mitochondria, no speciﬁc transport
mechanisms were assumed.
Anabolic demand of AGE1.HN
Macromolecules
The applied macromolecular composition of the cells was:
proteins, 70.6%; lipids, 9.2%; carbohydrates, 7.1%; DNA,
1.4%; RNA, 5.8%; rest/ash, 5.9%. The lipid composition
was determined once using 4.9 9 10
8 cells, harvested at a
cell density of 3.4 9 10
6 cells ml
-1 (viability 97%) using
a published protocol [22]. The other parts of the compo-
sition were taken from Bonarius et al. [21].
Amino acid composition
The amino acid composition of total cellular protein was
determined using samples of 1–2 9 10
7 cells that were
Fig. 1 Metabolic network used
for metabolic ﬂux analysis. PPP
pentose phosphate pathway,
TCA tricarboxylic acid; ETC
electron transport chain, OP
oxidative phosphorylation,
Carbo carbohydrates, Glc
glucose, Gal galactose, Lac
lactate, Pyr pyruvate, G6P
glucose 6-phosphate, P5P
pentose 5-phosphate, F6P
fructose 6-phosphate, GAP
glyceraldehyde 3-phosphate,
AcC acetyl coenzyme A, Cit
citrate, AKG a-ketoglutarate,
SuC succinyl coenzyme A, Fum
fumarate, Mal malate, OAA
oxaloacetate, ATP adenosine
triphosphate, ATPOP ATP from
oxidative phosphorylation,
ATPwOP ATP without oxidative
phosphorylation, ATPtot total
ATP, ATPexc ATP excess,
NADH nicotinamide adenine
dinucleotide, FADH2 ﬂavin
adenine dinucleotide, standard
abbreviations for amino acids.
Indices: m mitochondrial, ex
extracellular
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123washed twice with PBS to remove amino acids from the
medium. For hydrolysis 6 M HCl (280 ll/10
7 cells) was
used and incubated for 24 h at 110 C. The solution was
neutralized using 6 M NaOH and the amino acid compo-
sition was determined using HPLC as described above. The
determined relative composition (n = 4) was: aspartic
acid/asparagine, 9.25 ± 0.6%; glutamic acid/glutamine,
12.83 ± 0.48%; serine, 6.19 ± 0.12%; histidine, 2.18 ±
0.12%; glycine, 9.45 ± 0.67%; threonine, 4.94 ± 0.1%;
arginine, 5.19 ± 0.23%; alanine, 8.06 ± 0.09%; tyro-
sine, 1.9 ± 0.04%; valine, 6.14 ± 0.13%; phenylalanine,
3.56 ± 0.08%; isoleucine, 4.49 ± 0.09%; leucine, 8.71 ±
0.1%; lysine, 7.5 ± 0.17%; proline, 3.99 ± 0.12%. Methi-
onine, tryptophan and cysteine are degraded by the applied
hydrolytic method. Relative amounts for these amino acids
were taken from literature [37]: methionine, 1.7%; trypto-
phan, 1.1%; cysteine, 2.8%.
Cell dry weight estimation
The cell dry weight of mammalian cells in culture is not
constant and increases with increasing growth rate [38, 39].
It was shown, that the volume of cells is proportional to
their dry weight and can be used as an indirect measure of
the biomass concentration in the culture [38]. In this study,
cell size was determined using an automated cell culture
analyzer (Cedex AS20, Innovatis, Bielefeld, Germany)
providing an accurate determination of the cell diameter.
Assuming, that the cells are spherical, the respective cell
volume was calculated. The correlation between dry cell
weight, DCW (pg), and cell volume, CV (lm
3), determined
in a control experiment using the procedure described
previously [22], was DCW = 0.25 9 CV. This relation-
ship was used for calculation of biomass concentrations.
The anabolic demand of the cells is shown in Table 1.
Metabolic ﬂux analysis
The two different procedures applied for calculation of
metabolic ﬂuxes are depicted in Fig. 2. For the calculation
of metabolic ﬂuxes over time (dynamic method), splines
were ﬁtted to the measured data for biomass and extra-
cellular metabolites (Supplementary Fig. S1) using Matlab
7.5 (The Mathworks, Natick, MA, USA). These were used
to calculate speciﬁc rates (v) for each metabolite concen-
tration Mi over time using
Table 1 Anabolic demand of AGE1.HN
Macromolecule Anabolic demand (lmol g
-1 biomass)
Carbohydrates 438.3
DNA 45.3
RNA 180.3
Lipids 128.1
Proteins 6,433.0
Fig. 2 Methods applied for metabolic ﬂux analysis. Dynamic method
for calculation of the time course of metabolic ﬂuxes and stationary
method for calculation of mean ﬂuxes for different metabolic phases
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dMi=dt
B
ð3Þ
where B represents the respective biomass in the culture.
Intracellular ﬂuxes were calculated using
vk ¼ S 1
k    Sm   vm ðÞ ð 4Þ
where vm and vk represent the measured and the calculated
rate vectors. Sk and Sm are corresponding stoichiometric
matrices.
For calculating stationary ﬂuxes, growth was divided
into different metabolic phases (Fig. 2). Average rates for
each metabolite Mi were calculated assuming metabolic
steady state for each phase using the estimated speciﬁc
growth rate l and metabolite yields:
vMi ¼ l
DMi
DB
ð5Þ
B represents the total biomass in the culture. The data was
implemented into the metabolic network model and intra-
cellular ﬂuxes for each phase were subsequently calculated
using Eq. 4.
Results
Growth proﬁle of AGE1.HN during batch cultivation
During the initial growth period lasting up to 160 h the
viability remained high at about 95% (Fig. 3). At 160 h,
the viability started decreasing and the growth rate slowed
down. The cell density at the end of the batch cultivation
was about 7.5 9 10
6 cells ml
-1 (Fig. 3). By plotting the
logarithm of the cell density against time (not shown),
distinct growth phases could be distinguished. The ﬁrst
lasted from 0 to 90 h, the second from 90 to 160 h, the
third from 160 to 230 h, having growth rates of
0.351 ± 0.055, 0.279 ± 0.021 and 0.056 ± 0.011 d
-1.
Exometabolome analysis and extracellular ﬂuxes
The observed growth behavior is strongly linked to metab-
olite proﬁles (Fig. 4, Fig. S1). Pyruvate was consumed dur-
ing the ﬁrst 90 h of the cultivation (phase 1), and lactate,
glutamate, alanine and glycine were produced. The uptake
ratesofglucoseandpyruvateaswellastheproductionrateof
lactate were highest in the beginning and dropped until 90 h
(Fig. 5). The lactate production stopped with pyruvate
depletion at about 90 h indicating a coupling of these reac-
tions(Fig. 5).Theglutamateproductionratewasdecreasing
during the ﬁrst phase whereas the glutamine consumption
rate remained at a constant high value in this phase (Fig. 5).
For most other amino acids the uptake or production rates
were highest in phase 1 (Fig. S2, Table S2 and Table S3).
After 90 h (phase 2), when pyruvate was used up, lactate
production stopped immediately and the cells started to con-
sume glutamate as well as glycine (Fig. 4). The extracellular
Fig. 3 Growth of AGE1.HN. Viable cell density, total cell density
and viability during batch cultivation. Mean values and standard
deviations of four parallel cultivations
Fig. 4 Cultivation proﬁle of AGE1.HN. Mean values and standard
deviations for cell mass and selected metabolites of four parallel
cultivations are depicted. Further metabolites are depicted in Fig. S1 of
thesupplementarymaterial.Theﬁrstline(90 h)indicatestheendofthe
ﬁrstmetabolicphasewhenpyruvateisdepleted,thesecondline(160 h)
the end of the second metabolic phase when glutamine is depleted
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123ﬂuxes for most metabolites were signiﬁcantly lower than in
phase 1 (Fig. 6; Table S3). The glucose uptake rate that is
almostidenticaltotherateofglycolysiswas constant(Fig. 5)
and the lactate production rate was very low (Figs. 5, 6). The
glutamine uptake rate was decreasing (Fig. 5,T a b l eS 2 ) .A t
the end of phase 2, glutamine was nearly completely con-
sumed and the cells started to consume glutamate (Fig. 5;
Table S2). The production rate of alanine was decreasing
(Fig. 5; Fig. S2; Table S2). The rates for other amino acids
remained nearly constant or were very low (Fig. S2).
After 160 h (phase 3), glutamine was used up which
forced the cells to adapt their metabolism again. Glutamate
consumption increased initially in this phase. Lactate pro-
duction again increased slightly but was nevertheless very
low compared to phase 1 (Fig. 5; Table S3). Alanine, which
was constantly produced during phases 1 and 2, was now
consumed. In addition, the cells stopped exponential growth
and the viability dropped directly after glutamine depletion
which indicates the important role of glutamine as substrate
for AGE1.HN. Almost all of the calculated mean extracel-
lular ﬂuxes (Fig. 6; Table S3) were signiﬁcantly different as
compared to phase 1 and most of them were also signiﬁ-
cantly different as compared to phase 2. Glutamate was
completely exhausted at about 215 h (Fig. 4). The glucose
consumption rate was constantly decreasing until glucose
was completely depleted at the end of the cultivation at
230 h (Figs. 4, 5).
In general, the standard errors for extracellular ﬂuxes
were high in the beginning and decreased with time
(Fig. 5). This is due to the small differences in substrate
concentrations in the beginning of the cultivation. The
integral yield of cells per glucose was around 340 cells
nmol
-1 which is a favorable feature of AGE1.HN since
it is higher compared to the corresponding yield in CHO
cells which is typically ranging between 60 and 100
cells nmol
-1 of glucose consumed [25, 40].
Fig. 5 Selected metabolic
ﬂuxes of AGE1.HN over time
related to biomass. Mean values
and conﬁdence intervals (90%)
of four parallel cultivations. The
ﬂuxes (y-axis) are given in
lmol g
-1 h
-1 and the time
(x-axis) in days. The ﬁrst line
(90 h) indicates the end of the
ﬁrst metabolic phase when
pyruvate is consumed, the
second line (160 h) the end of
the second metabolic phase
when glutamine is consumed.
Negative values indicate ﬂuxes
in the opposite direction of the
arrow. Further extracellular and
intracellular ﬂuxes are depicted
in Fig. S2 and Fig. S3 of the
supplementary material
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Intracellular ﬂuxes were calculated using the stoichiome-
tric network model depicted in Fig. 1.
Glycolysis
The highest ﬂux through the glycolytic pathway was
observed in phase 1 (Fig. 6; Table S3). Then it was steadily
decreasing until 90 h (Fig. 5; Fig. S2). In phase 2, glyco-
lytic activity was signiﬁcantly lower and remained nearly
constant. In phase 3, glycolytic ﬂux was slightly decreasing
until the end of the cultivation (Fig. 5; Fig. S2) but was not
signiﬁcantly different from phase 2 (Fig. 6; Table S3).
Pyruvate dehydrogenase activity
The calculated ﬂuxes through the pyruvate carrier (Pyr-
Pyrm, Figs. 5, 6) and through the pyruvate dehydrogenase
complex (Pyrm-AcCm) were low in the beginning, i.e., not
signiﬁcantly different from zero (Table S3) and increased
in phase 1. In phase 2, pyruvate dehydrogenase activity
remained constant and was signiﬁcantly higher compared
to phase 1 (Figs. 5, 6; Table S3). Since lactate production
was approximately 0 in phase 2, most of the pyruvate was
entering the TCA cycle via pyruvate dehydrogenase. This
ﬂux was still high in phase 3 but slightly decreasing
(Fig. 5).
TCA cycle and anaplerosis
The activity of the TCA cycle in phase 1 was signiﬁcantly
lower than in phases 2 and 3 (Figs. 5, 6; Table S3). No
lactate was produced from pyruvate in phase 2. Therefore,
a large fraction of pyruvate entered the TCA cycle and
ﬂuxes through the upper part as well as the lower part of
the TCA cycle were very high in this phase (Figs. 5, 6;
Table S3). The anaplerotic ﬂux through the enzyme glu-
tamate dehydrogenase (Glu-AKGm) was decreasing during
the cultivation matching the decrease in available extra-
cellular glutamine (Fig. 5). The aspartate aminotransferase
ﬂux (Asp-OAAm) was highest in phase 1 and decreasing.
During phase 2, this ﬂux remained constant until it
decreased again in phase 3 (Fig. S3). Fluxes through the
TCA cycle in phase 3 were similar to those in phase 2 but
decreasing towards the end (Figs. 5, 6; Table S3). Gluta-
mine was depleted and glutamate was taken up instead
(Fig. 4). However, the ﬂux through glutamate dehydroge-
nase was very low in phase 3 which shows that acetyl
coenzyme A derived from pyruvate was by far the most
important fuel for TCA cycle after glutamine depletion.
The calculated ﬂux from malate to pyruvate (Malm-Pyrm)
was very high in the beginning of phase 1. In the following
phases, this ﬂux dropped and was signiﬁcantly lower
(Figs. 5, 6; Table S3). Interestingly during phase 1, the
TCA cycle was additionally fed by the degradation of the
branched chain amino acids isoleucin, leucin and valine. In
the other phases, degradation of these amino acids to form
intermediates of TCA cycle was not signiﬁcantly different
from zero.
Electron transport chain/oxidative phosphorylation
In accordance to the time courses for FADH2 and
NAD(P)H production, the activity of the oxidative phos-
phorylation (ATPOP) was low in phase 1 and then
increasing to a constant level during phase 2 until the
middle of phase 3 and subsequently decreasing (Fig. S3;
Fig. 6 Average metabolic ﬂux
distribution of AGE1.HN in
each metabolic phase. Flux
symbols selected for this ﬁgure
are shown in the ﬂux map of
phase 1 and are deﬁned in the
metabolic network (Fig. 1).
Same experiment as shown in
Fig. 5. Further data are provided
in Table S3 of the
supplementary material
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the network without oxidative phosphorylation (ATPwOP)
indicates that the ATP demand was also highest in phases 1
and 2 and lowest in phase 3.
Amino acid metabolism
The ﬂuxes through glutamine synthetase (Gln-Glu) and
glutamate dehydrogenase (Glu-AKGm) were almost con-
stant in phase 1 and then decreasing during the cultivation,
since glutamine and glutamate were successively depleted
(Figs. 5, 6; Table S3). The glutamate pool was additionally
fed by degradation of arginine (Arg-Glu, Fig. S3; Table
S3). In phases 1 and 2, less asparagine was taken up than
needed for protein synthesis which was then synthesized
through the asparagine synthase from aspartate (Asn-Asp,
Fig. S3; Table S3). Aspartate was feeding into the TCA
cycle during the whole cultivation through the aspartate
aminotransferase catalyzed reaction leading to oxaloacetate
(Asp-OAAm). This ﬂux was decreasing over time (Fig. S3).
Since glycine was produced in phase 1 and then only
slightly taken up (Fig. 4), it had to be produced via glycine
hydroxymethyltransferase indicated by Gly-Ser in Fig. S3
and Table S3. This ﬂux was signiﬁcantly decreasing with
time, because glycine was taken up in phases 2 and 3 where,
additionally, the anabolic demand was decreasing because
of slower growth. The ﬂux through serine dehydratase
(Ser-Pyr) was also signiﬁcantly decreasing (Fig. S3;
Table S3). In accordance with the time course of proline
production (Fig. 5), the ﬂux from glutamate to proline
(Pro-Glu, Fig. S3; Table S3) was highest in phase 1 and then
decreasing. Other degradation rates of amino acids were
very low indicating that the uptake of these amino acids was
just matching the anabolic demand of the cells.
Discussion
Metabolism in AGE1.HN
Metabolism and metabolic shifts of the new human cell
line AGE1.HN were quantitatively analyzed in this study
using time resolved metabolic ﬂux analysis and stationary
metabolic ﬂux analysis in different phases during batch
cultivation. Our results indicate that pyruvate uptake during
phase 1 in combination with high levels of other substrates
resulted in an inefﬁcient metabolic phenotype character-
ized by overﬂow metabolism leading to waste product
formation. In phase 2, the metabolism was switching to
a most efﬁcient state characterized by low substrate
uptake rates and no lactate formation. The data indicate
that a decrease in substrate levels occurring during the
cultivation resulted in a slowdown of glycolysis during
phase 1. Additional experiments using different pyruvate
concentrations in the medium support the conclusion that
there is a strong link between pyruvate in the medium and
lactate production in AGE1.HN (data will be presented
elsewhere). Another possibility would be that the cells
could secrete lactate only until a certain concentration is
reached and would then stop the production. However, in
other experiments that were performed using high lactate
start concentrations (about 8 mM) it was observed, that the
cells were producing almost the same amount of lactate as
in experiments where lactate start concentration was 0.
This indicates that pyruvate depletion seems to be an
important factor for cessation of lactate production. This
particular phenotype was so far not observed in other
mammalian cells [22, 23, 26, 41].
During exponential growth of mammalian cells under
non-limiting substrate levels inefﬁcient substrate utiliza-
tion was reported for several other mammalian cell
lines [22, 23, 28, 42]. Usually only a small amount of
intracellular pyruvate is entering the TCA cycle under
these conditions which is considered very unfavorable.
Increasing ﬂux through pyruvate dehydrogenase repre-
sents an optimization target for the cultivation of many
mammalian cells, but the mechanisms and molecular
reasons are still poorly understood [43, 44]. In a recent
study on HEK-293, cells pyruvate dehydrogenase activity
was reported to be around 22% of glycolytic activity [42].
Very low or even no activity of the pyruvate dehydro-
genase complex was reported in other studies on different
mammalian cells [23, 45]. In AGE1.HN cells, this was
observed only during the ﬁrst phase. During phases 2 and
3, pyruvate dehydrogenase activity was high. In MDCK
cells it was found that an addition of pyruvate in a
glutamine depleted medium resulted even in an increase
in the ﬂux from pyruvate into the TCA cycle [23]. In
AGE1.HN, it seems that available pyruvate has an
opposite effect triggering the conversion of pyruvate to
lactate. High uptake rates of glucose and pyruvate as
observed in phase 1 might lead to an increase of the
intracellular pyruvate pool triggering overﬂow metabolism
into lactate/alanine eventually resulting in an increased
secretion of these waste metabolites. This might be
changed by increasing reactions connecting TCA cycle
and glycolysis, e.g., by stimulating pyruvate dehydroge-
nase and pyruvate carboxylase ﬂuxes [46, 47]. However,
the success of this strategy can not be predicted a priori.
Increase of ﬂuxes into the TCA cycle must be accom-
panied by an increase in oxidative phosphorylation
activity which might not always be possible. Another
strategy that is working in the opposite direction would be
decreasing the substrate uptake rates, e.g., by knock down
of transporters [48] or decreasing the lactate production,
e.g., by knock down of lactate dehydrogenase [40].
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in AGE1.HN with those in other cells
Selected metabolic ﬂuxes in AGE1.HN that were calcu-
lated by the stationary method for different phases are
compared to ﬂuxes published for other mammalian cells
(Table 2). Glucose uptake and lactate production rates
were generally lower in AGE1.HN than in other cells.
Pyruvate represents an extracellular metabolite that was
often neglected in other studies [26, 28]. However, as
shown in this study and in MDCK cells [23, 49] or CHO
cells [50], it is a very interesting metabolite that can induce
huge changes in the metabolism. In AGE1.HN cells
pyruvate uptake rate was by far lower than in MDCK cells
that were grown in high pyruvate medium (Table 2, M2).
However, the ratio of pyruvate uptake per glucose uptake
was similar. The second phase in AGE1.HN showed a very
efﬁcient metabolism concerning substrate usage as already
discussed before. The cells were proliferating without
lactate production. Pyruvate dehydrogenase (PDH) activity
was high. In all other cell lines, high lactate production was
observed during the phases that were analyzed by MFA
except for CHO cells in presence of galactose after glucose
depletion. In order to reach higher cell densities in culti-
vations of AGE.HN, the second phase could be prolonged
by feeding of glutamine. PDH activity in AGE1.HN was
low in phase 1 and high in phases 2 and 3. A similar
situation was observed in CHO cells [26] which exhibited
low PDH activity and overﬂow metabolism during growth
on glucose. After glucose depletion, these cells were con-
suming lactate in the presence of galactose having high
PDH activity. No PDH activity was reported for MDCK
cells in glutamine containing medium. In medium without
glutamine and high pyruvate concentration low PDH
activity was found in these cells. The absolute ﬂux through
PDH was highest in continuously cultured hybridoma cells
[28], but the metabolism was by far not as efﬁcient as in
phase 2 of AGE1.HN since there was high glucose con-
sumption and waste product formation. Absolute glutamate
dehydrogenase (GDH) activity of AGE1.HN during phases
1 and 2 was lower than in other cell lines, but the relative
activity compared to the glucose uptake rate was quite
similar in MDCK and CHO cultures. Upper and lower
TCA cycle activity in phases 2 and 3 was similar to the
activity in CHO cells with glucose medium (S1 in Table 2)
and in MDCK cells (M2 in Table 2) cultured without
glutamine. For hybridoma cells, higher TCA cycle activity
was reported.
The main differences between the metabolic phases of
AGE1.HN are summarized in Fig. 7. The results indicate
Table 2 Comparison of selected metabolic ﬂuxes in AGE1.HN during different metabolic phases (P1–3) with ﬂuxes published for other
mammalian cell lines
Flux [lmol g
-1 h
-1]
AGE1.HN MDCK
a CHO
b Hybridoma
c
P1 P2 P3 M1 M2 S1 S2
Glc uptake 123 56.6 33.7 1,108.7 476.6 322.5 43.8
d 674.6
Pyr uptake 28.7 0.9 0.4 0 111 nd nd nd
Lac production 236.3 4.5 14.3 2,188 965 612.5 -68.8 1,030
Gln uptake 37.1 23.5 2.1 70.9 0.9 0 0 146.9
Glu production 4 -2.4 -2.9 -42.1 -22.1 -56.3 -56.8 1.2
PDH 12.2 88.1 56.8 0 33.1 35.5 174.6 355.7
GDH 13.2 8.3 1.7 64.7 42.8 28.1 14 110.1
Upper TCA -4 66.4 57.7 -27.3 43.5 35.5 148.8 312.5
Lower TCA 9.2 74.7 59.3 54.3 63 78.9 195.8 441.1
Fluxes are given in lmol g
-1 h
-1. Literature ﬂuxes that were given per cell were normalized to biomass by assuming a cell dry weight of
800 pg cell
-1 for MDCK cells [24] and 400 pg cell
-1 for CHO and hybridoma cells [21, 60]
MDCK murine darby canine kidney, M1 glutamine containing medium, M2 medium with high pyruvate concentration and without glutamine,
CHO chinese hamster ovary, S1 stage 1 of cultivation, S2 stage 2 of cultivation when glucose is exhausted, Glc glucose, Pyr pyruvate, Lac
lactate, Gln glutamine, Glu glutamate, PDH pyruvate dehydrogenase, GDH glutamate dehydrogenase, upper TCA activity of the upper
tricarboxylic acid cycle represented by the ﬂux from citrate to a-ketoglutarate, lower TCA activity of the lower TCA cycle represented by the
a-ketoglutarate dehydrogenase ﬂux (glutamate to a-ketoglutarate), nd not determined
a MDCK cell culture [23]
b CHO cell culture [26]
c Continuous culture of hybridoma cells [28]
d Galactose uptake
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123further targets for improving the metabolic phenotype of
these cells to reach higher cell densities as well as to obtain
a more efﬁcient utilization of the nutrients. The high
overﬂow metabolism in the beginning of the cultivation
with channeling of pyruvate to lactate could be decreased.
This could be accomplished by genetic engineering, e.g.,
deletion of lactate dehydrogenase [51] or introduction of
pyruvate carboxylase [46], further medium optimization,
e.g., reduced concentrations of pyruvate, or application of
new feeding strategies [50]. The observed metabolism in
phase 2 indicates the potential of this cell line to grow very
efﬁciently having minimum formation of waste products
and minimum energy spilling [52]. Therefore, it seems
promising to change environmental conditions, i.e., media,
substrate feeding as well as enzyme expression such as to
approach the efﬁcient metabolic state of phase 2 during a
process. Studies on enzyme expression and detailed
labelling experiments in combination with
13C metabolic
ﬂux analysis would provide additional hints for the best
way to further improve the cell line.
Time resolved versus stationary ﬂux analysis
The applied dynamic method is well suited to analyze and
monitor metabolic shifts during the cultivation. Cell
growth, cell size, extracellular as well as intracellular
ﬂuxes of mammalian cells in a cell culture process are
highly dynamic which is caused by environmental changes.
Therefore, the presented method that is considering the
dynamics of all included metabolites and biomass is best
suited to understand and ﬁnally model the process. Sta-
tionary metabolic ﬂux analysis that was applied extensively
in the past [23, 53] is only suited to describe the mean
metabolism during a certain phase which is a signiﬁcant
disadvantage since changes during the phase considered
are neglected [54]. However, if the pseudo steady state
assumption during a phase is justiﬁed, it can give a useful
overview of its average metabolism [55]. The information
obtained by ﬂux balance analysis can be validated [56]o r
further enriched by speciﬁc labelling information [57]t o
resolve reversible, cyclic or parallel ﬂuxes as for example
pentose phosphate pathway split [58, 59].
Concluding remarks
The application of a dynamic metabolic ﬂux analysis
method as presented in this study is well suited to describe
the dynamic and adaptive behavior of the metabolism of
mammalian cells during cultivation in industrially relevant
media at any scale. Thus, it supports the identiﬁcation of
targets for improved growth and substrate utilization based
on derived metabolic ﬂux distribution. Further improve-
ment of the method could be achieved by including
labelling information as for example to monitor pentose
phosphate pathway split. The presented dynamic method
can be applied to almost any cultivation of a mammalian
cell and could replace the widely applied but inﬂexible
stationary MFA. In this study, metabolic shifts caused by
changing environmental conditions during cultivation of
AGE1.HN cells were described in detail (Fig. 7). This
knowledge about the reaction of the cells to changes in the
environment is a valuable basis for designing efﬁcient
Fig. 7 Summary of metabolic shifts during batch cultivation of
AGE1.HN
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123feeding strategies but also providing hints for genetic
modiﬁcations. In the AGE1.HN cell line major targets
identiﬁed for improvement are as follows: (i) overﬂow
metabolism during phase 1 should be reduced, e.g., by
reduction of pyruvate content in the medium, (ii) phase 2
should be prolonged by speciﬁc feeding strategies, e.g., of
glutamine. The dynamic metabolic ﬂux data presented in
this study contribute to the attempted systems level of
understanding of this cell line that is expected to eventually
improve heterologous protein production in a cell produc-
ing a heterologous protein. Generally, the method repre-
sents a valuable option to support today and future
improvement of cell culture media and processes.
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